DK3075745T3 - Muterede interleukin-2-polypeptider - Google Patents
Muterede interleukin-2-polypeptider Download PDFInfo
- Publication number
- DK3075745T3 DK3075745T3 DK16164244.2T DK16164244T DK3075745T3 DK 3075745 T3 DK3075745 T3 DK 3075745T3 DK 16164244 T DK16164244 T DK 16164244T DK 3075745 T3 DK3075745 T3 DK 3075745T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- polypeptide
- sequence
- mutant
- immunoconjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (17)
1. Immunkonjugat, der omfatter et muteret IL-2-polypeptid og en antigenbindende del, hvor det muterede IL-2-polypeptid omfatter sekvensen ifølge SEQ ID NO: 19 og hvor den antigenbindende del er et IgGi-underklasse-immunglobulinmolekyle, der er specifikt for Fibroblast Activation Protein (FAP), omfattende (i) sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 41 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 39, (ii) sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 51 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 49, (iii) sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 111 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 109, (iv) sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 143 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 141 eller (v) sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 151 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 149.
2. Immunkonjugat ifølge krav 1, hvor det muterede IL-2-polypeptid er forbundet ved sin aminoterminale aminosyre til den carboxyterminale aminosyre af en af immunglobulintungkædeme.
3. Immunkonjugat ifølge krav 1 eller 2, hvor immunkonjugatet omfatter ikke mere end ét muteret IL-2-polypeptid.
4. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 3, hvor IgGi-underklasse-immunglobulinmolekylet i Fc-domænet omfatter en ”knob-into-hole”-modifikation, der omfatter en ”knob”-modifikation i den ene af immunglobulintungkædeme og en ”hole”-modifikation i den anden af immunglobulintungkædeme, hvor ”knob”-modifikationen omfatter aminosyresubstitutionen T366W i den ene af de to immunglobulintungkæder, og ”hole”-modifikationen omfatter aminosyresubstitutionerne T366S, L368A og Y407V i den anden af de to immunglobulintungkæder.
5. Immunkonjugat ifølge krav 4, hvor immunglobulintungkæden, der omfatter ”knob”-modifikationen, yderligere omfatter aminosyresubstitutionen S354C, og immunglobulintungkæden, der omfatter ”hole”-modifikationen, yderligere omfatter aminosyresubstitutionen Y349C.
6. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 5, hvor IgG i-molekylet omfatter aminosyremutationerne L234A, L235A og P329G i sit Fc-domæne.
7. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 6, der omfatter (i) en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 297, en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 299 og en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 233, (ii) en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 301, en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 303 og en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 231 eller (iii) en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 315, en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 317 og en polypeptidsekvens, der er mindst 80 %, 85 %, 90 %, 95 %, 96 %, 97 %, 98 %, 99 % eller 100 % identisk med SEQ ID NO: 233.
8. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 7, hvor IgGi-mo lekylet, der er specifikt for FAP, omfatter sekvensen af den variable tungkæderegion ifølge SEQ ID NO: 111 og sekvensen af den variable letkæderegion ifølge SEQ ID NO: 109.
9. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 8, der omfatter en polypeptidsekvens ifølge SEQ ID NO: 301, en polypeptidsekvens ifølge SEQ ID NO: 303 og en polypeptidsekvens ifølge SEQ ID NO: 231.
10. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 9, der består af et muteret IL-2-polypeptid og et IgGi-molekyle forbundet med en linkersekvens.
11. Isoleret polynukleotid, der koder for immunkonjugatet ifølge et hvilket som helst af kravene 1 til 10.
12. Værtscelle, der omfatter polynukleotidet ifølge krav 11.
13. Fremgangsmåde til fremstilling af et immunkonjugat, der omfatter et muteret IL-2-polypeptid og en antigenbindende del, hvilken fremgangsmåde omfatter dyrkning af værtscellen ifølge krav 12 under betingelser, der er egnede til ekspression af immunkonjugatet.
14. Immunkonjugat, der omfatter et muteret IL-2-polypeptid og en antigenbindende del, der er fremstillet ved hjælp af fremgangsmåden ifølge krav 13, hvor det muterede IL-2-polypeptid omfatter sekvensen ifølge SEQ ID NO: 19, og hvor den antigenbindende del er et IgGi-underklasse-immunglobulinmolekyle, der er specifikt for FAP.
15. Farmaceutisk sammensætning, der omfatter immunkonjugatet ifølge et hvilket som helst af kravene 1 til 10 eller 14 og en farmaceutisk acceptabel bærer.
16. Immunkonjugat ifølge et hvilket som helst af kravene 1 til 10 eller 14 til anvendelse i behandlingen af en sygdom hos en person med behov derfor.
17. Immunkonjugat til anvendelse i behandlingen af en sygdom ifølge krav 16, hvor sygdommen er cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11153964 | 2011-02-10 | ||
EP11164237 | 2011-04-29 | ||
EP12702045.1A EP2673294B1 (en) | 2011-02-10 | 2012-02-07 | Mutant interleukin-2 polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3075745T3 true DK3075745T3 (da) | 2018-11-26 |
Family
ID=45560919
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16164244.2T DK3075745T3 (da) | 2011-02-10 | 2012-02-07 | Muterede interleukin-2-polypeptider |
DK12702045.1T DK2673294T3 (da) | 2011-02-10 | 2012-02-07 | Mutante interleukin-2-polypeptider |
DK18191941.6T DK3489255T3 (da) | 2011-02-10 | 2012-02-07 | Muterede interleukin-2-polypeptider |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12702045.1T DK2673294T3 (da) | 2011-02-10 | 2012-02-07 | Mutante interleukin-2-polypeptider |
DK18191941.6T DK3489255T3 (da) | 2011-02-10 | 2012-02-07 | Muterede interleukin-2-polypeptider |
Country Status (36)
Country | Link |
---|---|
US (5) | US9266938B2 (da) |
EP (4) | EP2673294B1 (da) |
JP (2) | JP5878182B2 (da) |
KR (2) | KR101667096B1 (da) |
CN (3) | CN112210000A (da) |
AR (1) | AR085335A1 (da) |
AU (2) | AU2012215573B2 (da) |
BR (1) | BR112013018932B1 (da) |
CA (1) | CA2824253C (da) |
CL (1) | CL2013001987A1 (da) |
CO (1) | CO6741186A2 (da) |
CR (1) | CR20130314A (da) |
CY (1) | CY1117842T1 (da) |
DK (3) | DK3075745T3 (da) |
EA (1) | EA033369B1 (da) |
EC (1) | ECSP13012815A (da) |
ES (3) | ES2883371T3 (da) |
HK (1) | HK1217020A1 (da) |
HR (3) | HRP20160917T1 (da) |
HU (3) | HUE055284T2 (da) |
IL (3) | IL269687B (da) |
LT (2) | LT3489255T (da) |
MA (1) | MA35803B1 (da) |
MX (2) | MX340671B (da) |
MY (1) | MY190604A (da) |
PE (2) | PE20181077A1 (da) |
PH (1) | PH12017500954B1 (da) |
PL (3) | PL3489255T3 (da) |
PT (3) | PT2673294T (da) |
RS (3) | RS62238B1 (da) |
SG (2) | SG192673A1 (da) |
SI (3) | SI3489255T1 (da) |
TW (2) | TWI577801B (da) |
UA (2) | UA117294C2 (da) |
WO (1) | WO2012107417A1 (da) |
ZA (1) | ZA201305282B (da) |
Families Citing this family (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
EA034742B1 (ru) | 2010-08-13 | 2020-03-16 | Роше Гликарт Аг | Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения |
RS62238B1 (sr) | 2011-02-10 | 2021-09-30 | Roche Glycart Ag | Mutantni interleukin-2 polipeptidi |
JP6046642B2 (ja) * | 2011-03-02 | 2016-12-21 | ロシュ グリクアート アーゲー | Cea抗体 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP2714912B1 (en) | 2011-06-01 | 2018-05-02 | Intrexon Actobiotics NV | Polycistronic expression system for bacteria |
CA2844540C (en) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
JP2015537043A (ja) * | 2012-11-30 | 2015-12-24 | ロシュ グリクアート アーゲー | 多機能タンパク質を含むがん細胞標的化mhcクラスiを用いた循環性ウイルス特異的細胞傷害性t細胞によるがん細胞の除去 |
ES2700984T3 (es) | 2012-12-21 | 2019-02-20 | Hoffmann La Roche | Proteínas multifuncionales que comprenden MHC de clase I multivalente unida por disulfuro |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP3708584A1 (en) | 2013-02-26 | 2020-09-16 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
CA2896370A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
DK2970486T3 (da) | 2013-03-15 | 2018-08-06 | Xencor Inc | Modulering af t-celler med bispecifikke antistoffer og fc-fusioner |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
DK3041854T3 (da) | 2013-08-08 | 2020-03-02 | Scripps Research Inst | En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider |
BR112016018288A2 (pt) | 2014-02-06 | 2017-10-10 | Hoffmann La Roche | proteínas de fusão de interleucina 2 e uso das mesmas |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
EP3943607A1 (en) | 2014-04-09 | 2022-01-26 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US10894828B2 (en) | 2014-07-10 | 2021-01-19 | Universität Zürich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
EP3172227B9 (en) * | 2014-07-21 | 2020-01-08 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
BR112016030462A2 (pt) | 2014-08-04 | 2018-01-16 | F. Hoffmann-La Roche Ag | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo |
AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
LT3186283T (lt) * | 2014-08-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Kombinuotoji terapija į naviką nutaikytais il-2 imunocitokinais ir antikūnais prieš žmogaus pd-l1 |
MX2020012798A (es) | 2014-11-14 | 2022-04-07 | Hoffmann La Roche | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. |
WO2016079050A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2881374T3 (es) | 2014-12-15 | 2021-11-29 | Univ Washington | Composiciones y procedimientos para la administración direccionada de citoquinas |
US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
JP6996979B2 (ja) | 2015-03-31 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 三量体tnfファミリーリガンドを含む抗原結合分子 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CA2990755A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffman-La Roche Ag | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
US10287352B2 (en) | 2015-10-02 | 2019-05-14 | Hoffman-La Roche Inc. | Bispecific antibodies specific for PD1 and TIM3 |
US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
CA3003969A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
SG11201804259UA (en) | 2015-12-04 | 2018-06-28 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
KR20180100224A (ko) | 2016-01-11 | 2018-09-07 | 노바르티스 아게 | 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질 |
AU2017208153B2 (en) | 2016-01-14 | 2021-01-28 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
EP3411414A4 (en) | 2016-02-05 | 2019-10-23 | Washington University | COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF |
US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
PE20231511A1 (es) | 2016-03-22 | 2023-09-26 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3 |
CN109689087B (zh) | 2016-05-13 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | 靶向性突变干扰素-β及其用途 |
WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
DK3475295T3 (da) | 2016-06-24 | 2022-10-24 | Scripps Research Inst | Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf |
US10316088B2 (en) | 2016-06-28 | 2019-06-11 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
WO2018060301A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Bispecific antibodies against cd3 |
BR112019007288A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente |
CN109952370B (zh) * | 2016-10-19 | 2023-09-08 | 豪夫迈·罗氏有限公司 | 用于产生免疫缀合物的方法 |
JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン-ガンマおよびその使用 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
EP3558339B1 (en) * | 2016-12-22 | 2024-01-24 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
AU2018216032B2 (en) | 2017-02-06 | 2022-04-07 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US20200010528A1 (en) * | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
MA49033B1 (fr) * | 2017-04-03 | 2022-10-31 | Hoffmann La Roche | Immunoconjugué d'un anticorps contre pd-1 avec il-2 mutée ou avec il-15 |
EP3606947B1 (en) * | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
PE20200006A1 (es) * | 2017-04-04 | 2020-01-06 | Hoffmann La Roche | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap |
UA128451C2 (uk) | 2017-04-05 | 2024-07-17 | Ф. Хоффманн-Ля Рош Аг | Біспецифічне антитіло, яке специфічно зв'язується з pd1 і lag3 |
ES2880366T3 (es) * | 2017-04-11 | 2021-11-24 | Hoffmann La Roche | Retrotranscriptasa mutante con un incremento en la estabilidad térmica así como productos, procedimientos y usos que involucran la misma |
CN110505883A (zh) | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
KR20200010354A (ko) | 2017-05-24 | 2020-01-30 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
EA201992765A1 (ru) | 2017-05-24 | 2020-03-25 | Новартис Аг | Белки на основе антител с привитым цитокином и способы их применения в лечении рака |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
CA3069321A1 (en) | 2017-07-11 | 2019-01-17 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
MX2020001332A (es) * | 2017-08-03 | 2020-09-09 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas. |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2019129053A1 (zh) * | 2017-12-26 | 2019-07-04 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
CA3115461A1 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
WO2019185705A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
CN112154153A (zh) * | 2018-03-28 | 2020-12-29 | 百时美施贵宝公司 | 白介素-2/白介素-2受体α融合蛋白以及使用方法 |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
CN112771072A (zh) * | 2018-07-24 | 2021-05-07 | 生物技术Rna制药有限公司 | Il2激动剂 |
CN117925531A (zh) * | 2018-08-01 | 2024-04-26 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
US12049485B2 (en) * | 2018-09-11 | 2024-07-30 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
EP4403635A2 (en) * | 2018-09-17 | 2024-07-24 | GI Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
AR114732A1 (es) | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
US20210221863A1 (en) * | 2018-09-21 | 2021-07-22 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
CA3098765A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
BR112021005907A2 (pt) * | 2018-09-27 | 2021-08-10 | Xilio Development, Inc. | citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit |
CN113195523A (zh) | 2018-10-03 | 2021-07-30 | Xencor股份有限公司 | IL-12异源二聚体Fc融合蛋白 |
EP3870598A1 (en) * | 2018-10-23 | 2021-09-01 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
AU2019371994A1 (en) * | 2018-10-29 | 2021-06-03 | 1Globe Biomedical Co., Ltd. | Novel rationally designed protein compositions |
EP3875475A4 (en) * | 2018-12-21 | 2022-12-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | VARIANT OF HUMAN INTERLEUKIN-2 OR ITS DERIVATIVE |
JP2022514343A (ja) | 2018-12-21 | 2022-02-10 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 腫瘍標的化アゴニストcd28抗原結合分子 |
US20220025050A1 (en) | 2018-12-21 | 2022-01-27 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
WO2020130300A1 (ko) * | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 |
CN113924311A (zh) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | 包含修饰的il-2多肽的多肽及其用途 |
US11529402B2 (en) | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
BR112021014415A2 (pt) | 2019-02-06 | 2021-09-21 | Synthorx, Inc. | Conjugados de il-2 e métodos de uso dos mesmos |
JP2022523946A (ja) | 2019-03-01 | 2022-04-27 | ゼンコア インコーポレイテッド | Enpp3およびcd3に結合するヘテロ二量体抗体 |
CN111647068A (zh) * | 2019-03-04 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
CN111944008A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种突变蛋白的方法以及得到的突变体蛋白 |
CN111944036A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
KR20220012296A (ko) | 2019-05-20 | 2022-02-03 | 싸이튠 파마 | 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법 |
WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
US11879145B2 (en) | 2019-06-14 | 2024-01-23 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
US20220170028A1 (en) * | 2019-06-14 | 2022-06-02 | Cugene Inc | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
JP2022538139A (ja) | 2019-07-02 | 2022-08-31 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体 |
JP2022544771A (ja) * | 2019-08-12 | 2022-10-21 | アスクジーン・ファーマ・インコーポレイテッド | 優先的にil-2rアルファに結合するil-2融合タンパク質 |
US20230203119A1 (en) | 2019-08-15 | 2023-06-29 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
WO2021055568A1 (en) * | 2019-09-19 | 2021-03-25 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
KR20220113674A (ko) | 2019-09-27 | 2022-08-16 | 인트랙슨 액토바이오틱스 엔.브이. | 셀리악 병의 치료 |
WO2021101270A1 (ko) | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 |
CA3157613A1 (en) | 2019-11-20 | 2021-05-27 | Gi Cell, Inc. | Medium composition for culturing t cells and method for culturing t cells using same |
CN117004564A (zh) | 2019-11-20 | 2023-11-07 | 吉爱希公司 | 调节性t细胞培养组合物及其用途 |
CA3157575A1 (en) | 2019-11-27 | 2021-06-03 | Myoung Ho Jang | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein |
TWI820361B (zh) * | 2019-11-27 | 2023-11-01 | 南韓商Gi醫諾微新股份有限公司 | 包含含有il-2蛋白與cd80蛋白之融合蛋白及免疫檢查點抑制劑的用於治療癌症的藥學組成物 |
CN114524873A (zh) | 2019-12-17 | 2022-05-24 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
JP2023507115A (ja) | 2019-12-17 | 2023-02-21 | アムジエン・インコーポレーテツド | 治療における使用のためのデュアルインターロイキン-2/tnf受容体アゴニスト |
WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
KR20220125806A (ko) * | 2020-01-09 | 2022-09-14 | 화이자 인코포레이티드 | 재조합 백시니아 바이러스 |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
AU2021207901A1 (en) | 2020-01-14 | 2022-09-08 | Synthekine, Inc. | IL2 orthologs and methods of use |
CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
TWI839476B (zh) * | 2020-02-26 | 2024-04-21 | 大陸商北京泰德製藥股份有限公司 | 介白素-2多肽共軛物及其用途 |
US20230125871A1 (en) | 2020-03-18 | 2023-04-27 | Gi Innovation, Inc. | Fusion protein preparation comprising il-2 and cd80 proteins |
CN115989238A (zh) | 2020-03-18 | 2023-04-18 | Gi医诺微新 | 包含il-2蛋白和cd80蛋白片段或其变体的融合蛋白及其用途 |
BR112022018631A2 (pt) | 2020-03-18 | 2022-11-08 | Gi Innovation Inc | Composição farmacêutica para tratar câncer, compreendendo proteína de fusão compreendendo proteína il-2 e proteína cd80 e fármaco anticâncer |
TWI790573B (zh) * | 2020-03-19 | 2023-01-21 | 大陸商信達生物製藥(蘇州)有限公司 | 白介素2突變體及其用途 |
CN115315437A (zh) | 2020-03-19 | 2022-11-08 | 信达生物制药(苏州)有限公司 | 白介素2突变体及其用途 |
US20230151072A1 (en) * | 2020-04-01 | 2023-05-18 | Xilio Development, Inc. | Masked il-2 cytokines and their cleavage products |
MX2022012541A (es) | 2020-04-15 | 2022-11-07 | Hoffmann La Roche | Inmunoconjugados. |
EP4139341A1 (en) | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof |
JP7415047B2 (ja) | 2020-04-22 | 2024-01-16 | メルク・シャープ・アンド・ドーム・エルエルシー | インターロイキン-2受容体βγc二量体について偏向され、非ペプチド性水溶性ポリマーにコンジュゲートされたヒトインターロイキン-2コンジュゲート |
IL298038A (en) | 2020-05-11 | 2023-01-01 | Hoffmann La Roche | Combined treatment with modified pbmcs and an immune couple |
GB2621482A (en) | 2020-05-13 | 2024-02-14 | Bonum Therapeutics Inc | Compositions of protein complexes and methods of use thereof |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
AU2021286177A1 (en) | 2020-06-03 | 2022-12-01 | Ascendis Pharma Oncology Division A/S | IL-2 sequences and uses thereof |
KR102373965B1 (ko) | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
TWI811703B (zh) | 2020-06-19 | 2023-08-11 | 瑞士商赫孚孟拉羅股份公司 | 與cd3及cd19結合之抗體 |
KR20230025783A (ko) | 2020-06-19 | 2023-02-23 | 에프. 호프만-라 로슈 아게 | 면역 활성화 Fc 도메인 결합 분자 |
KR102313505B1 (ko) | 2020-06-30 | 2021-10-18 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법 |
TW202221031A (zh) | 2020-07-30 | 2022-06-01 | 英商阿法克塔生命科學有限公司 | 血清半衰期延長之pd-l1抑制多肽 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ, インコーポレイテッド | 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法 |
WO2022059794A1 (ja) * | 2020-09-18 | 2022-03-24 | 地方独立行政法人 宮城県立病院機構 | Il-2変異体タンパク質及びこれを含む医薬 |
CN114380919B (zh) * | 2020-10-18 | 2024-06-25 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
CN114369153A (zh) * | 2020-10-18 | 2022-04-19 | 北京志道生物科技有限公司 | 一种白介素-2突变体 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
CA3195276A1 (en) | 2020-10-26 | 2022-05-05 | Stefano FERRARA | Il-2/il-15rb?? agonist for treating non-melanoma skin cancer |
AU2021369823A1 (en) | 2020-10-29 | 2023-06-01 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
MX2023005458A (es) | 2020-11-13 | 2023-05-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que comprende una variante de la interleucina humana 2 o un derivado de la misma y uso de la misma. |
CN112724259B (zh) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
MX2023006480A (es) | 2020-12-04 | 2023-06-19 | Hoffmann La Roche | Polipeptidos de interleucina-2 mutante dependientes del ph. |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
US20240262913A1 (en) | 2021-03-09 | 2024-08-08 | Hoffmann-La Roche Inc. | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
JP2024508949A (ja) | 2021-03-09 | 2024-02-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
KR20230162013A (ko) | 2021-03-26 | 2023-11-28 | 이나뜨 파르마 에스.에이. | Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질 |
EP4314032A1 (en) | 2021-03-30 | 2024-02-07 | F. Hoffmann-La Roche AG | Protease-activated polypeptides |
AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
CN113321722A (zh) * | 2021-04-13 | 2021-08-31 | 苏州复融生物技术有限公司 | 白介素2突变体及其应用 |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
CA3227227A1 (en) | 2021-06-09 | 2022-12-15 | Laurent Gauthier | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
MX2023014647A (es) | 2021-06-09 | 2024-01-31 | Innate Pharma | Proteinas de union a nkp46 multiespecificas. |
WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
US20240158537A1 (en) | 2021-07-09 | 2024-05-16 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
CA3224147A1 (en) | 2021-07-09 | 2023-01-12 | Vijaya Raghavan PATTABIRAMAN | Antibody conjugates and manufacture thereof |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
EP4366782A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
MX2024002261A (es) | 2021-08-24 | 2024-03-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molecula de union de fap/cd40 y uso medicinal de la misma. |
KR20240067081A (ko) * | 2021-09-26 | 2024-05-16 | 우시 바이올로직스 아일랜드 리미티드 | Il-2 변이체 및 이의 융합 단백질 |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
EP4416174A1 (en) | 2021-10-14 | 2024-08-21 | F. Hoffmann-La Roche AG | New interleukin-7 immunoconjugates |
CU20210104A7 (es) | 2021-12-21 | 2023-07-12 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 |
KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
US20230303650A1 (en) * | 2022-01-21 | 2023-09-28 | Aetio Biotherapy, Inc. | Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies |
CA3189227A1 (en) * | 2022-02-21 | 2023-05-01 | Ctcells, Inc. | A fusion protein comprising an antigen binding domain and a cytokine trimer domain |
US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
TW202413442A (zh) | 2022-06-16 | 2024-04-01 | 美商希佛隆有限責任公司 | 抗pd-1抗體減弱之il-2免疫結合物及其用途 |
TW202409069A (zh) * | 2022-07-01 | 2024-03-01 | 大陸商北京星奇原生物科技有限公司 | Il-2多肽和使用方法 |
US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
TW202413398A (zh) * | 2022-08-16 | 2024-04-01 | 國立陽明交通大學 | 介白素-2變異體及其於治療癌症的用途 |
WO2024068705A1 (en) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Protease-activated polypeptides |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
WO2024119193A2 (en) | 2022-12-02 | 2024-06-06 | AskGene Pharma, Inc. | Mutant il-2 polypeptides and il-2 prodrugs |
WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
WO2024153725A1 (en) | 2023-01-20 | 2024-07-25 | F. Hoffmann-La Roche Ag | Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR7801185A (pt) | 1977-04-18 | 1978-11-28 | Hitachi Metals Ltd | Ornato adaptado para ser fixado por pelo menos um ima permanente |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19607751A1 (de) | 1996-02-29 | 1997-09-04 | Henkel Kgaa | Neue Aminophenol-Derivate und deren Verwendung |
IL129354A0 (en) | 1996-10-18 | 2000-02-17 | Genentech Inc | Anti-ErbB2 antibodies |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6455677B1 (en) | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
MXPA01008110A (es) | 1999-02-12 | 2002-10-23 | Scripps Research Inst | Metodos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias anti-angiogenicas e inmunoterapia. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
CA2401252A1 (en) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
JP4936299B2 (ja) | 2000-08-21 | 2012-05-23 | メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ | 磁場方向検出センサ |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
AR036330A1 (es) | 2001-04-13 | 2004-09-01 | Biogen Inc | Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
EP1476180A4 (en) | 2001-08-13 | 2005-04-20 | Univ Southern California | INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY |
CN100390282C (zh) * | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
PT1572748E (pt) * | 2002-12-17 | 2010-09-28 | Merck Patent Gmbh | Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2 |
EP1587921B1 (en) | 2003-01-22 | 2010-07-28 | GlycArt Biotechnology AG | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
BRPI0417990A (pt) | 2003-12-22 | 2007-04-27 | Chiron Corp | uso de polimorfismos de receptor fc como diagnósticos para estratégias de tratamento para distúrbios de resposta imune |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
DE602006012667D1 (de) | 2005-05-11 | 2010-04-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
CA2663832C (en) | 2006-09-20 | 2013-02-05 | Dge Dr.-Ing. Guenther Engineering Gmbh | Method and device for separating methane and carbon dioxide from biogas |
CN101678079B (zh) | 2006-11-28 | 2013-12-25 | 韩诺生物制约株式会社 | 修饰的促红细胞生成素多肽及其治疗用途 |
MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
CA2694396A1 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binding agents directed to kdr and uses thereof - 035 |
EP2018877A1 (en) | 2007-07-27 | 2009-01-28 | The Procter and Gamble Company | Absorbent article comprising water-absorbing polymeric particles and method for the production thereof |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
ATE548052T1 (de) | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
CN102119175A (zh) | 2008-04-10 | 2011-07-06 | Ibc药品公司 | 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法 |
ES2389474T3 (es) | 2008-05-13 | 2012-10-26 | Molmed Spa | Conjugados para el tratamiento del mesotelioma |
EP2382228B1 (en) * | 2009-01-21 | 2020-08-26 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
AU2010208125B2 (en) | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
AU2010230063B2 (en) * | 2009-03-24 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
US20120107270A1 (en) | 2009-06-30 | 2012-05-03 | Manuela Kaspar | Immunocytokines In Combination With Anti-ErbB Antibodies For The Treatment Of Cancer |
WO2011020783A2 (en) * | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Targeted immunoconjugates |
AU2010288469A1 (en) | 2009-08-31 | 2012-03-01 | Roche Glycart Ag | Affinity-matured humanized anti CEA monoclonal antibodies |
DK2483310T3 (da) | 2009-09-29 | 2014-09-01 | Roche Glycart Ag | Bispecifik dødsreceptor-agonistiske antistoffer |
EA034742B1 (ru) | 2010-08-13 | 2020-03-16 | Роше Гликарт Аг | Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
RS62238B1 (sr) | 2011-02-10 | 2021-09-30 | Roche Glycart Ag | Mutantni interleukin-2 polipeptidi |
JP6046642B2 (ja) | 2011-03-02 | 2016-12-21 | ロシュ グリクアート アーゲー | Cea抗体 |
CN103476795B (zh) | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | 抗体Fc变体 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
CN104540848B (zh) | 2012-08-08 | 2019-05-31 | 罗切格利卡特公司 | 白介素-10融合蛋白及其用途 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
KR20160005345A (ko) | 2013-05-07 | 2016-01-14 | 에프. 호프만-라 로슈 아게 | 삼량체성 항원 결합 분자 |
LT3186283T (lt) | 2014-08-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Kombinuotoji terapija į naviką nutaikytais il-2 imunocitokinais ir antikūnais prieš žmogaus pd-l1 |
-
2012
- 2012-02-07 RS RS20210996A patent/RS62238B1/sr unknown
- 2012-02-07 BR BR112013018932-0A patent/BR112013018932B1/pt active IP Right Grant
- 2012-02-07 CA CA2824253A patent/CA2824253C/en active Active
- 2012-02-07 PT PT127020451T patent/PT2673294T/pt unknown
- 2012-02-07 MY MYPI2013701387A patent/MY190604A/en unknown
- 2012-02-07 KR KR1020137020938A patent/KR101667096B1/ko active IP Right Grant
- 2012-02-07 HU HUE18191941A patent/HUE055284T2/hu unknown
- 2012-02-07 SG SG2013060207A patent/SG192673A1/en unknown
- 2012-02-07 ES ES18191941T patent/ES2883371T3/es active Active
- 2012-02-07 SG SG10201604160WA patent/SG10201604160WA/en unknown
- 2012-02-07 CN CN202010954354.5A patent/CN112210000A/zh active Pending
- 2012-02-07 RS RS20181250A patent/RS57767B1/sr unknown
- 2012-02-07 LT LTEP18191941.6T patent/LT3489255T/lt unknown
- 2012-02-07 TW TW101103928A patent/TWI577801B/zh active
- 2012-02-07 UA UAA201611547A patent/UA117294C2/uk unknown
- 2012-02-07 PL PL18191941T patent/PL3489255T3/pl unknown
- 2012-02-07 DK DK16164244.2T patent/DK3075745T3/da active
- 2012-02-07 MX MX2013009226A patent/MX340671B/es active IP Right Grant
- 2012-02-07 ES ES12702045.1T patent/ES2579987T3/es active Active
- 2012-02-07 EP EP12702045.1A patent/EP2673294B1/en active Active
- 2012-02-07 CN CN201510970941.2A patent/CN105440123B/zh active Active
- 2012-02-07 MX MX2016006214A patent/MX356675B/es unknown
- 2012-02-07 EP EP21178401.2A patent/EP3971206A1/en not_active Withdrawn
- 2012-02-07 HU HUE16164244A patent/HUE040326T2/hu unknown
- 2012-02-07 AU AU2012215573A patent/AU2012215573B2/en active Active
- 2012-02-07 PL PL12702045.1T patent/PL2673294T3/pl unknown
- 2012-02-07 ES ES16164244.2T patent/ES2694564T3/es active Active
- 2012-02-07 IL IL269687A patent/IL269687B/en unknown
- 2012-02-07 DK DK12702045.1T patent/DK2673294T3/da active
- 2012-02-07 EP EP16164244.2A patent/EP3075745B1/en active Active
- 2012-02-07 US US13/367,843 patent/US9266938B2/en active Active
- 2012-02-07 PE PE2018000181A patent/PE20181077A1/es unknown
- 2012-02-07 KR KR1020157020539A patent/KR101852245B1/ko active IP Right Grant
- 2012-02-07 DK DK18191941.6T patent/DK3489255T3/da active
- 2012-02-07 RS RS20160397A patent/RS54802B1/sr unknown
- 2012-02-07 EP EP18191941.6A patent/EP3489255B1/en active Active
- 2012-02-07 SI SI201231940T patent/SI3489255T1/sl unknown
- 2012-02-07 WO PCT/EP2012/051991 patent/WO2012107417A1/en active Application Filing
- 2012-02-07 PE PE2013001855A patent/PE20140303A1/es active IP Right Grant
- 2012-02-07 CN CN201280017730.1A patent/CN103492411B/zh active Active
- 2012-02-07 SI SI201231430T patent/SI3075745T1/sl unknown
- 2012-02-07 SI SI201230620A patent/SI2673294T1/sl unknown
- 2012-02-07 PT PT16164244T patent/PT3075745T/pt unknown
- 2012-02-07 HU HUE12702045A patent/HUE029139T2/hu unknown
- 2012-02-07 EA EA201300896A patent/EA033369B1/ru not_active IP Right Cessation
- 2012-02-07 JP JP2013552930A patent/JP5878182B2/ja active Active
- 2012-02-07 UA UAA201310726A patent/UA113729C2/uk unknown
- 2012-02-07 PT PT181919416T patent/PT3489255T/pt unknown
- 2012-02-07 LT LTEP16164244.2T patent/LT3075745T/lt unknown
- 2012-02-07 PL PL16164244T patent/PL3075745T3/pl unknown
- 2012-02-07 TW TW106101987A patent/TWI666027B/zh not_active IP Right Cessation
- 2012-02-08 AR ARP120100412A patent/AR085335A1/es active IP Right Grant
-
2013
- 2013-06-20 IL IL227095A patent/IL227095B/en active IP Right Grant
- 2013-06-24 CR CR20130314A patent/CR20130314A/es unknown
- 2013-06-25 CO CO13150839A patent/CO6741186A2/es unknown
- 2013-07-05 CL CL2013001987A patent/CL2013001987A1/es unknown
- 2013-07-12 ZA ZA2013/05282A patent/ZA201305282B/en unknown
- 2013-08-09 EC ECSP13012815 patent/ECSP13012815A/es unknown
- 2013-09-10 MA MA36237A patent/MA35803B1/fr unknown
-
2014
- 2014-03-27 HK HK16105003.6A patent/HK1217020A1/zh unknown
-
2015
- 2015-05-20 JP JP2015102866A patent/JP6155300B2/ja not_active Expired - Fee Related
- 2015-10-28 AU AU2015249085A patent/AU2015249085B2/en not_active Ceased
-
2016
- 2016-01-15 US US14/996,789 patent/US10323098B2/en active Active
- 2016-07-21 CY CY20161100718T patent/CY1117842T1/el unknown
- 2016-07-21 HR HRP20160917TT patent/HRP20160917T1/hr unknown
-
2017
- 2017-05-11 IL IL25223017A patent/IL252230B/en active IP Right Grant
- 2017-05-24 PH PH12017500954A patent/PH12017500954B1/en unknown
- 2017-12-20 US US15/849,501 patent/US10184009B2/en active Active
-
2018
- 2018-10-22 HR HRP20181736TT patent/HRP20181736T1/hr unknown
- 2018-11-21 US US16/198,531 patent/US11111312B2/en active Active
-
2019
- 2019-06-17 US US16/443,306 patent/US20190322765A1/en not_active Abandoned
-
2021
- 2021-08-16 HR HRP20211318TT patent/HRP20211318T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3075745T3 (da) | Muterede interleukin-2-polypeptider | |
AU2017202437B2 (en) | Novel immunoconjugates | |
CN110719920B (zh) | 蛋白质异二聚体及其用途 | |
KR102648966B1 (ko) | Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자 | |
KR102042246B1 (ko) | 인터류킨-2 융합 단백질 및 이의 용도 | |
KR102361237B1 (ko) | 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물 | |
CN109575140B (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
KR101901458B1 (ko) | Tcr 복합체 면역치료제 | |
KR20210013156A (ko) | 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도 | |
KR20210062749A (ko) | 다량체 il-15 기반 분자 | |
CN109311973A (zh) | 含有c端融合的tnf家族配体三聚体的抗原结合分子 | |
KR20150041628A (ko) | 인터루킨-2 융합 단백질 및 그의 용도 | |
KR20180054877A (ko) | 공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체 | |
KR20180053674A (ko) | 공자극 tnf 수용체에 특이적인 이중특이성 항체 | |
KR20170081267A (ko) | T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법 | |
KR20140016262A (ko) | 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법 | |
KR20150122203A (ko) | T 세포 활성화 이중특이적 항원 결합 분자 | |
KR20100021601A (ko) | 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 | |
KR20110043643A (ko) | 인터루킨 6 면역치료제 | |
CN111051350A (zh) | 包含信号调节蛋白α的免疫缀合物 | |
KR20230027300A (ko) | Il-10 뮤테인 및 이의 융합 단백질 | |
KR20230017841A (ko) | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
KR20230165829A (ko) | 이중특이적 분자 및 관련 조성물 및 방법 |